March 27, 2017 11:57 AM ET

Pharmaceuticals

Company Overview of Wacker Biotech GmbH

Company Overview

Wacker Biotech GmbH offers contract manufacturing of pharmaceutical proteins. Wacker Biotech GmbH was formerly known as Prothera GmbH. The company was founded in 1999 and is based in Jena, Germany. As of January 11, 2005, Wacker Biotech GmbH operates as a subsidiary of Wacker chemistry AG.

Hans Knöll Straße 3

Jena,  07745

Germany

Founded in 1999

Phone:

49 3641 65 8270

Fax:

49 3641 65 8271

Key Executives for Wacker Biotech GmbH

Wacker Biotech GmbH does not have any Key Executives recorded.

Wacker Biotech GmbH Key Developments

Wacker Biotech GmbH Presents at Baader Investment Conference 2016, Sep-20-2016 through Sep-22-2016

Wacker Biotech GmbH Presents at Baader Investment Conference 2016, Sep-20-2016 through Sep-22-2016. Venue: Sofitel Munich Bayerpost, Bayerstrasse 12, Munich 80335, Germany. Presentation Date & Speakers: Sep-20-2016, Thomas Maier, Managing Director Wacker Biotech GmbH location Jena. Sep-21-2016, Thomas Maier, Managing Director.

Wacker Biotech GmbH Presents at 2016 BIO International Convention, Jun-07-2016 03:45 PM

Wacker Biotech GmbH Presents at 2016 BIO International Convention, Jun-07-2016 03:45 PM. Venue: Moscone Center, San Francisco, California, United States.

Wacker Biotech Announces License Agreement with MedImmune

Wacker Biotech GmbH has announced a license agreement with MedImmune, a biologics R&D arm of AstraZeneca, for the use of its ESETEC 2.0 proprietary secretion technology in E.coli. This agreement now gives MedImmune the right to use WACKER's ESETEC 2.0 cell line exclusively for the production and commercialization of an antibody fragment (Fab), which will benefit MedImmune with improved productivity and a simplified purification process as compared to conventional E. coli processes. This agreement follows a feasibility study that the companies conducted, which demonstrated that WACKER's ESETEC2.0 technology was superior to existing technologies for the production of Fabs. Fabs are purpose-made constituents of human antibodies and represent a highly promising growth area for the pharmaceutical industry. The ESETEC 2.0 technology provided a high yield of correctly folded and biologically active Fab. The technology also exhibited enhanced productivity, which outperformed industrially optimized processes for mammalian cell cultures (CHO cells). Based on this successful study, both parties agreed to produce the Fab at one of Wacker's cGMP (current Good Manufacturing Practice) facilities.

Similar Private Companies By Industry

Company Name Region
3B Pharmaceuticals GmbH Europe
Accelsiors Group International Europe
Aenova Group GmbH Europe
Aenova Holding GmbH Europe
AiCuris GmbH & Co. KG Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Wacker Biotech GmbH, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.